Table 2.

Characteristics of patients with RA.

	RA, n = 223
Disease duration, months	84 (123)
ACPA positivity, %	70.4
RF positivity, %	74.6
ESR, mm/h	21 (24)
CRP, mg/dl	0.37 (0.6)
CDAI	4 (10)
Glucocorticoids use, %	29.2
Glucocorticoids dose, mg/day	5 (2)
Cumulative dosage glucocorticoids, g	1.5 (0.7)
Methotrexate use, %	81.1
Cumulative dosage methotrexate, g	3.6 (5.04)
Leflunomide use, %	4.05
TNFi use, %	20.2
Tocilizumab use, %	4.9
Abatacept use, %	1.8
Rituximab use, %	0.9

ACPA, anti-citrullinated peptide antibodies; CDAI, clinical disease activity index; CRP, C-reactive protein concentrations, mg/dl; ESR, erythrocyte sedimentation rate, mm/h; IQR, interquartile range; RA, rheumatoid arthritis; RF, rheumatoid factor; sDMARDs, synthetic disease-modifying anti-rheumatic drugs; TNFi, tumour necrosis factor inhibitors.

Values are median (IQR).